drugset / Trial / NCT00301457

Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer

NCT00301457

Phase 3 Completed 1914 enrolled Maastricht University Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether 6 years adjuvant anastrozole will improve the disease free survival compared to 3 years adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2-3 years tamoxifen

Timeline

Start
2006-06
Primary completion
2022-04
Completion
2022-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg Oral

Indications